Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Bristol Myers Squibb•December 05, 2025 at 11:15 AM•Pending
View Original →Content
No content available yet. Click "View Original" above to read the full story.